ASCO Guideline Update for PARP Inhibitors in the Management of Ovarian Cancer Now Open for Public Comment

The American Society of Clinical Oncology (ASCO) is now seeking public comment for an upcoming guideline update.

ASCO's PARP Inhibitors in the Management of Ovarian Cancer is now open for public comment through July 21, 2025.

After signing a confidentiality agreement, individuals can view the proposed guideline and then submit feedback by the comment period's deadline.

Copyright ® 2025 Guideline Central, all rights reserved.